Pembrolizumab plus lenvatinib for brain metastases from solid tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 2 trial studies whether combining pembrolizumab with lenvatinib can shrink or control brain metastases in people with triple-negative breast cancer, lung cancer, or other solid tumors. It focuses on patients who have measurable brain lesions that can be followed on MRI.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent
- You have brain metastases from TNBC, NSCLC, or another solid tumor type (measurable on MRI)
- Your brain metastasis measurements are stable enough for repeated MRI checks (with specific size limits)
- You may have had prior SRS or surgery for up to 5 brain spots if you recovered and measurable lesions remain
- Your other body functioning tests are good enough (blood counts, liver/kidney tests, and blood clotting)
- Your overall condition is fairly strong (ECOG 0–1) and you can likely live at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether pembrolizumab (an immune therapy medicine) plus stereotactic radiosurgery (focused radiation) can better control brain metastases from breast cancer. It may help shrink or slow growth of multiple brain spots with minimal treatment to surrounding tissue.
This trial tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to the brain and has not been treated before. The goal is to see if this combination can shrink tumors in the brain and elsewhere.
This trial tests a combination of two drugs, alpelisib and pembrolizumab, for people with advanced triple-negative breast cancer or melanoma that has spread. The goal is to see if the combination can help shrink tumors, including those that have spread to the brain.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
Hear when a new Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.